Dalfampridine Market – Extended-Release Therapy Improving Walking Ability in Multiple Sclerosis
Market Overview The dalfampridine market continues to hold clinical relevance as this extended-release potassium channel blocker remains a recognized option for improving walking ability in patients with multiple sclerosis. Unlike disease-modifying therapies, dalfampridine addresses a specific functional symptom, offering measurable mobility improvement for eligible patients. The Dalfampridine...
0 Comentários 0 Compartilhamentos 3 Visualizações 0 Anterior
Uddokta 64 https://uddokta64.com